Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome

Genes Chromosomes and Cancer

Volumn 48, Issue 7, 2009, Pages 558-568

  Rieber, Juliane ^b   Remke, Marc ^b   Hartmann, Christian ^a,b   Korshunov, Andrey ^a,b   Burkhardt, Birgit ^c   Sturm, Dominik ^b   Mechtersheimer, Gunhild ^a   Wittmann, Andrea ^b   Greil, Johann ^a   Blattmann, Claudia ^a   Witt, Olaf ^a,b   Behnisch, Wolfgang ^a   Halatsch, Marc Eric ^a   Orakcioglu, Berk ^a   Von Deimling, Andreas ^a,b   Lichter, Peter ^b   Kulozik, Andreas ^a   Pfister, Stefan ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IDARUBICIN; NUCLEAR PROTEIN; PROTEIN MYCN; PROTEIN P53; TRANSCRIPTION FACTOR GLI2; TROFOSFAMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CHILD; CHOROID PLEXUS TUMOR; CONTROLLED STUDY; EPENDYMOMA; FAMILIAL CANCER; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; RHABDOID TUMOR; SCHOOL CHILD;

CHILD; CHOROID PLEXUS NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LI-FRAUMENI SYNDROME; LOSS OF HETEROZYGOSITY; MALE; MEDULLOBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEDIGREE; RHABDOID TUMOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67449093705     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20665     Document Type: Article

References (50)

1. Abe Y, Oda-Sato E, Tobiume K, Kawauchi K, Taya Y, Okamoto K, Oren M, Tanaka N. 2008. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc Natl Acad Sci USA 105:4838-4843. (Pubitemid 351753833)
2. Adhikary S, Eikers M. 2005. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6:635-645. (Pubitemid 41081267)
3. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM. 1998. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17:1061-1068. (Pubitemid 28444590)
4. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PHM, Binchy A, Crowther D, Craft AW, Eden OB, D. Evans GR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibáñez-Kore MF. 1994. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298-1304. (Pubitemid 24108072)
5. Bourdeaut F, Fréneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Couturier J, Pierron G, Sainte-Rose C, Bergeron C, Bouvier R, Rialland X, Laurence V, Michon J, Sastre-Garau X, Delattre O. 2007. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 211:323-330.
6. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi O-P. 1999. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806. (Pubitemid 29086730)
7. Burkhardt B, Bruch J, Zimmermann M, Strauch K, Parwaresch R, Ludwig WD, Harder L, Schlegelberger B, Mueller F, Harbott J, Reiter A. 2006. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 20:1422-1429. (Pubitemid 44084056)
8. Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunteun J, Bonaiti-Pellie C. 2001. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43-47. (Pubitemid 32102322)
9. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Paillerets BB, Frébourg T, Lemerle J, Bonaïti-Pellié C, Feunteun J. 2000. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932-1937.
10. Eberharc CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC. 2002. Brain Pathol 12:36-44.
11. Freies RA. 1995. Germline mutations in the TP53 gene. Cancer Surv 25:101-124. (Pubitemid 26065308)
12. Evans DG, Birch JM, Narod SA. 2008. Is CHEK2 a cause of the Li Fraumeni syndrome? J Med Genet 45:63-64.
13. Fogarty MP, Kessler JD, Wechsler-Reya RJ. 2005. Morphing into cancer: The role of developmental signaling pathways in brain tumor formation. J Neurobiol 64:458-475. (Pubitemid 41114053)
14. Giagounidis AAN, Germing U, Aul C. 2006. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 12:5-10. (Pubitemid 43166169)
15. Giagounidis AAN, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. 2005. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84:569-571. (Pubitemid 41194542)
16. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN. 2009. Beyond Li Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250-1256.
17. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, Kundgen A, Lubbert M, Kunzmann R, Giagounidis AA, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C. 2007. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110:4385-4395.
18. Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A. 2003. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22:5358-5361.
19. Hwang S-J, Lozano G, Amos CI, Strong LC. 2003. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet 72:975-983. (Pubitemid 36403315)
20. Inokuchi K, Miyake K, Takahashi H, Dan K, Nomura T. 1996. DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis. J Clin Invest 97:852-857. (Pubitemid 26057105)
21. Junttila MR, Westermarck J. 2008. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7:592-596.
22. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424-8429.
23. Ko LJ, Prives C. 1996. p53: Puzzle and paradigm. Genes Dev 10:1054-1072. (Pubitemid 26152848)
24. Kortmann R-D, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiesder O, Sörensen N, Warmuth-Metz M, Bamberg M. 2000. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the german prospective randomized trial hit '91. Int J Radiat Oncol Biol Phys 46:269-279. (Pubitemid 30067775)
25. Krejci P, Pejchalova K, Rosenbloom BE, Rosenfelt FP, Tran EL, Laurell H, Wilcox WR. 2007. The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia. J Leuk Biol 82:1363-1364. (Pubitemid 350276945)
26. Krutilkova V, Trkova M, Fleitz J, Gregor V, Novotna K, Krepelova A, Sumerauer D, Kodet R, Siruckova S, Plevova P, Bendova S, Hedvicakova P, Foreman NK, Sedlacek Z. 2005. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer 41:1597-1603.
27. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA. 2001. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 61: 8062-8067.
28. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331. (Pubitemid 27131374)
29. Li FP, Fraumeni JF, Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747-752.
30. Li FP, Fraumeni JF, Jr., Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5562. (Pubitemid 18220645)
31. Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A, Scheithauer B, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
32. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238. (Pubitemid 120031831)
33. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G Korshunov A, Lichter P. 2005. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23:8853-8862. (Pubitemid 46211532)
34. Mori N, Morosetti R, Hoflehner E, Lubbert M, Mizoguchi H, Koeffler HP. 2000. Allelic loss in the progression of myelodysplastic syndrome. Cancer Res 60:3039-3042. (Pubitemid 30395832)
35. Niemeyer C. 2006. Clinical Trial Protocol; EWOG-MDS 2006; Prospective non-randomized multi-center study forepidemiology and characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) in childhood. Freiburg: University Hospital Freiburg, Germany.
36. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. 2003. Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643-6650. (Pubitemid 37322942)
37. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629. (Pubitemid 46744292)
38. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A. 2009. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q, 17q, and the MYC and MYCN loci. J Clin Oncol 27:1627-1636.
39. Sasaki H, Moriyama S, Yukiue H, Kobayashi Y, Nakashima Y, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. 2001. Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in non-small cell lung cancer. Lung Cancer 34:53-57. (Pubitemid 32824123)
40. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J. 1998. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16:2478-2485. (Pubitemid 28309044)
41. Schiffman JD, Chun N, Fisher PG, Dahl GV, Ford JM, Eggerding FA. 2007. Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. Pediatr Blood Cancer 50:914-916.
42. Schutz BR, Scheurlen W, Krauss J, du Manoir S, Joos S, Bentz M, Lichter P. 1996. Mapping of chromosomal gains and losses in primitive neuroectodermal tumors by comparative genomic hybridization. Genes Chromosomes Cancer 16: 196-203.
43. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Döhner H, Cremer T, Lichter P. 1997. Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20:399-407.
44. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. 1990. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749. (Pubitemid 120015153)
45. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H. 2001. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: Further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61:5718-5722.
46. van Dartel M, Hulsebos TJM. 2004. Amplification and overexpression of genes in 17p11.2-p12 in osteosarcoma. Cancer Genet Cytogenet 153:77-80. (Pubitemid 39592135)
47. Varley JM. 2003. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21:313-320. (Pubitemid 36292974)
48. Vita M, Henriksson M. 2006. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16:318-330. (Pubitemid 44311040)
49. Weiss MM, Hermsen MA, Meijer GA, van Grieken NC, Baak JP, Kuipers EJ, van Diest PJ. 1999. Comparative genomic hybridisation. Mol Pathol 52:243-251.
50. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE, Radlwimmer B, Lohmann DR, Lichter P. 2005. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosom Cancer 43:294-301.